1. Prevalence of micronutrient deficiencies and relationship with clinical and patient-related outcomes in pulmonary hypertension types i and iv
- Author
-
Paulien Vinke, T. (Thomas) Koudstaal, A.M. (Femke) Muskens, A.E. (Annemien) van den Bosch, Michiel Balvers, Mieke Poland, Renger F. Witkamp, Klaske van Norren, K.A.T. (Karin) Boomars, Paulien Vinke, T. (Thomas) Koudstaal, A.M. (Femke) Muskens, A.E. (Annemien) van den Bosch, Michiel Balvers, Mieke Poland, Renger F. Witkamp, Klaske van Norren, and K.A.T. (Karin) Boomars
- Abstract
Background: Pulmonary hypertension (PH) is a rare progressive and lethal disease affecting pulmonary arteries and heart function. The disease may compromise the nutritional status of the patient, which impairs their physical performance. This study aimed to determine the prevalence of micronutrient deficiencies in pulmonary arterial hypertension (PAH) and chronic thrombo-embolic pulmonary hypertension (CTEPH) patients. Methods: Eighty-one blood samples from a prospective observational cohort study were analyzed for concentrations of micronutrients and inflammation-related factors. The samples consisted of newly diagnosed (treatment-naive) PAH and CTEPH patients and patients treated for 1.5 years according to ERS/ESC guidelines. Results: In the newly diagnosed group, 42% of PAH patients and 21% of CTEPH patients were iron deficient compared to 29% of PAH patients and 20% of CTEPH patients in the treatment group. Vitamin D deficiency occurred in 42% of the newly diagnosed PAH patients, 71% of the newly diagnosed CTEPH patients, 68% of the treated PAH patients, and 70% of the treated CTEPH patients. Iron levels correlated with the 6 min walking distance (6MWD). Conclusions: Iron and vitamin D deficiencies are highly prevalent in PAH and CTEPH patients, underlining the need for monitoring their status. Studies evaluating the effects of supplementation strategies for iron and vitamin D are necessary.
- Published
- 2021
- Full Text
- View/download PDF